Last reviewed · How we verify
Placebo of Iron Carboxymaltose
This is a placebo control arm and contains no active pharmaceutical ingredient.
This is a placebo control arm and contains no active pharmaceutical ingredient. Used for Control arm in iron deficiency anemia trials.
At a glance
| Generic name | Placebo of Iron Carboxymaltose |
|---|---|
| Also known as | Saline |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is inert and produces no pharmacological effect. It is used in clinical trials as a control comparator to evaluate the efficacy and safety of the active iron carboxymaltose formulation. Any observed effects in the placebo group represent baseline disease progression or non-specific responses.
Approved indications
- Control arm in iron deficiency anemia trials
Common side effects
Key clinical trials
- The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension (PHASE4)
- Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery (PHASE4)
- IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study (PHASE2, PHASE3)
- Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial (NA)
- Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion (PHASE4)
- The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly (NA)
- Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) (PHASE3)
- Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Iron Carboxymaltose CI brief — competitive landscape report
- Placebo of Iron Carboxymaltose updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI